Plasma MicroRNAs Are Altered Early and Consistently in a Mouse Model of Tauopathy
Authors:
- 1 July 2019
- journal article
- research article
- Published by Elsevier in Neuroscience
- Vol. 411, 164-176
Abstract
No abstract availableKeywords
Funding Information
- Brain Research New Zealand - Rangahau Roro Aotearoa
This publication has 45 references indexed in Scilit:
- Tolfenamic Acid: A Modifier of the Tau Protein and its Role in Cognition and TauopathyCurrent Alzheimer Research, 2018
- Whole transcriptome profiling of Late-Onset Alzheimer’s Disease patients provides insights into the molecular changes involved in the diseaseScientific Reports, 2018
- Grey matter atrophy in prodromal stage of dementia with Lewy bodies and Alzheimer’s diseaseAlzheimer's Research & Therapy, 2016
- Specific Targeting of Tau Oligomers in Htau Mice Prevents Cognitive Impairment and Tau Toxicity Following Injection with Brain-Derived Tau Oligomeric SeedsJournal of Alzheimer’s Disease, 2014
- Assessing sample and miRNA profile quality in serum and plasma or other biofluidsMethods, 2013
- Microarray analysis of CA1 pyramidal neurons in a mouse model of tauopathy reveals progressive synaptic dysfunctionNeurobiology of Disease, 2012
- Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasmaProceedings of the National Academy of Sciences, 2011
- Cell-Cycle Reentry and Cell Death in Transgenic Mice Expressing Nonmutant Human Tau IsoformsJournal of Neuroscience, 2005
- MicroRNAsCell, 2004
- Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoformsJournal of Neurochemistry, 2003